Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 6/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 6/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 5/20 | 0.44 |
| ▸ | GABRR1 | P24046 | 5/20 | 0.44 |
| ▸ | GABRA4 | P48169 | 5/20 | 0.44 |
| ▸ | SLC6A12 | P48065 | 4/20 | 0.44 |
| ▸ | SLC6A13 | Q9NSD5 | 4/20 | 0.44 |
| ▸ | SLC6A1 | P30531 | 3/20 | 0.44 |
| ▸ | SLC6A11 | P48066 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL715379 | 0.96 | GABRA5 (0.47) | GABRA5GABRB2GABRA1GABRR1GABRA4 | |
| SCHEMBL2920078 | 0.85 | GABRA5 (0.44) | GABRA5GABRB2GABRA1GABRR1GABRA4 | |
| SCHEMBL2918420 | 0.83 | GABRA5 (0.46) | GABRA5GABRB2GABRA1GABRR1GABRA4 | |
| SCHEMBL946968 | 0.79 | SLC6A1 (0.33) | GABRA5GABRB2GABRA1GABRR1GABRA4 | |
| SCHEMBL2914156 | 0.78 | SLC6A1 (0.36) | GABRA5GABRB2GABRA1GABRR1GABRA4 | |
| SCHEMBL2911229 | 0.76 | SLC6A1 (0.32) | GABRA5GABRB2GABRA1GABRR1GABRA4 | |
| SCHEMBL1233220 | 0.76 | — | — | |
| SCHEMBL717330 | 0.75 | SLC6A1 (0.31) | GABRA5GABRB2GABRA1GABRR1GABRA4 | |
| SCHEMBL2650750 | 0.75 | TSHR (0.33) | GABRA5GABRB2GABRA1GABRR1GABRA4 | |
| SCHEMBL11524373 | 0.74 | SLC6A1 (0.37) | GABRA5GABRB2GABRA1GABRR1GABRA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9682153-B2 | Polymer conjugates of therapeutic peptides | NEKTAR THERAPEUTICS (US) | 2017-06-20 | — | — | US | disclosed |
| US-20160022828-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NEKTAR THERAPEUTICS | 2016-01-28 | — | — | US | disclosed |
| US-9173951-B2 | Carbohydrate-based drug delivery polymers and conjugates thereof | NEKTAR THERAPEUTICS (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150051371-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | NEKTAR THERAPEUTICS (US) | 2015-02-19 | — | — | US | disclosed |
| US-8680263-B2 | Carbohydrate-based drug delivery polymers and conjugates thereof | NEKTAR THERAPEUTICS (US) | 2014-03-25 | — | — | US | disclosed |
| US-20110171716-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
| EP-1594851-A1 | TRIMERIC MACROCYCLICALLY SUBSTITUTED BENZENE DERIVATIVES | Schering Aktiengesellschaft (DE) | 2005-11-16 | — | — | EP | disclosed |
| WO-2004074267-A1 | TRIMERIC MACROCYCLICALLY SUBSTITUTED BENZENE DERIVATIVES | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160022828-A1 | POLYMER CONJUGATES OF THERAPEUTIC PEPTIDES | NGLY1, CD44, IAPP | GABRA5 1508/4885GABRB2 2948/4885GABRA1 2184/4885 |
| US-20110171716-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | STT3B, STT3A, DDOST | GABRA5 4284/4885GABRB2 4157/4885GABRA1 4163/4885 |
| US-20150051371-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | STT3B, STT3A, DDOST | GABRA5 4284/4885GABRB2 4157/4885GABRA1 4163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.